[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$bioa](/topic/$bioa) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "💼 $GOOGL Google $AMPX Amprius Technologies $NTLA Intellia Therapeutics $MDXH MDxHealth $AIRO Airo Group $OSSD OssDsign $SGMO Sangamo Therapeutics $SRPT Sarepta Therapeutics $NKTR Nektar Therapeutics $MCLAIR Medclair $NOVO Novo Nordisk $BIOA BioArctic" [X Link](https://x.com/Drbagholders/status/1975612700110794883) [@Drbagholders](/creator/x/Drbagholders) 2025-10-07T17:22Z XXX followers, 1307 engagements "$BIOA $ESAIY Leqembi Iqlik (lecanemab-irmb) maintenance treatment launched in the United States BioArctic partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October X 2025 as a maintenance option for early Alzheimers disease (MCI or mild dementia) after an initial 18-month IV induction. After XX months of XX mg/kg IV every two weeks patients may continue IV every four weeks or switch to a weekly XXX mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education financial/insurance support an injection" [X Link](https://x.com/MarcJacksonLA/status/1975332616623825261) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-06T22:49Z 7581 followers, XXX engagements "$VTYX Have still my shares from the first data run up in spring/summer. Sanofi has first right to negotiate here. Smells like something coming. NLRP3 is en vogue right now. $ROG showed their own NLRP3 some weeks ago. $BIOA also with NLRP3 data end of the year" [X Link](https://x.com/Lord_of_Biotech/status/1973401285551427705) [@Lord_of_Biotech](/creator/x/Lord_of_Biotech) 2025-10-01T14:55Z 3309 followers, 2680 engagements "$BIOA $ESAIY Leqembi approved for IV maintenance treatment in China BioArctic announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of XX mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing. Leqembi initially approved in China in January 2024 is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration" [X Link](https://x.com/MarcJacksonLA/status/1972551114496393485) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-09-29T06:36Z 7581 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"💼 $GOOGL Google $AMPX Amprius Technologies $NTLA Intellia Therapeutics $MDXH MDxHealth $AIRO Airo Group $OSSD OssDsign $SGMO Sangamo Therapeutics $SRPT Sarepta Therapeutics $NKTR Nektar Therapeutics $MCLAIR Medclair $NOVO Novo Nordisk $BIOA BioArctic"
X Link @Drbagholders 2025-10-07T17:22Z XXX followers, 1307 engagements
"$BIOA $ESAIY Leqembi Iqlik (lecanemab-irmb) maintenance treatment launched in the United States BioArctic partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October X 2025 as a maintenance option for early Alzheimers disease (MCI or mild dementia) after an initial 18-month IV induction. After XX months of XX mg/kg IV every two weeks patients may continue IV every four weeks or switch to a weekly XXX mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education financial/insurance support an injection"
X Link @MarcJacksonLA 2025-10-06T22:49Z 7581 followers, XXX engagements
"$VTYX Have still my shares from the first data run up in spring/summer. Sanofi has first right to negotiate here. Smells like something coming. NLRP3 is en vogue right now. $ROG showed their own NLRP3 some weeks ago. $BIOA also with NLRP3 data end of the year"
X Link @Lord_of_Biotech 2025-10-01T14:55Z 3309 followers, 2680 engagements
"$BIOA $ESAIY Leqembi approved for IV maintenance treatment in China BioArctic announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of XX mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing. Leqembi initially approved in China in January 2024 is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration"
X Link @MarcJacksonLA 2025-09-29T06:36Z 7581 followers, XXX engagements
/topic/$bioa/posts